Immunocore is a commercial-stage biotechnology company that discovered, developed and commercialized the world’s first approved T cell receptor (TCR) therapy.

Their mission is to radically improve outcomes for patients with cancer, infectious diseases, and autoimmune diseases, by pioneering and delivering transformative immunomodulating medicines.

Built on proprietary ImmTAX platform, they have a diverse pipeline of bispecific therapies across a broad range of indications, including multiple cancers, HIV and HBV